Analysts Set TESARO Inc (TSRO) Target Price at $106.33

Shares of TESARO Inc (NASDAQ:TSRO) have received a consensus rating of “Buy” from the twenty-three brokerages that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and fifteen have issued a buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $106.33.

A number of equities analysts have commented on the stock. Robert W. Baird restated a “hold” rating on shares of TESARO in a research note on Tuesday, April 24th. BidaskClub downgraded shares of TESARO from a “sell” rating to a “strong sell” rating in a research note on Friday, April 20th. Lake Street Capital set a $120.00 target price on shares of TESARO and gave the stock a “buy” rating in a research note on Sunday, April 22nd. Argus dropped their target price on shares of TESARO from $154.00 to $110.00 and set a “buy” rating on the stock in a research note on Wednesday, May 2nd. Finally, Credit Suisse Group dropped their target price on shares of TESARO from $141.00 to $128.00 and set an “outperform” rating on the stock in a research note on Friday, May 4th.

In other news, Director Lawrence M. Alleva sold 7,142 shares of the company’s stock in a transaction that occurred on Tuesday, June 12th. The shares were sold at an average price of $43.11, for a total value of $307,891.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 33.70% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. First Mercantile Trust Co. lifted its position in TESARO by 1,136.0% during the second quarter. First Mercantile Trust Co. now owns 8,108 shares of the biopharmaceutical company’s stock valued at $360,000 after acquiring an additional 7,452 shares during the last quarter. Capital Impact Advisors LLC lifted its position in TESARO by 67.3% during the second quarter. Capital Impact Advisors LLC now owns 37,524 shares of the biopharmaceutical company’s stock valued at $1,660,000 after acquiring an additional 15,089 shares during the last quarter. Trellus Management Company LLC lifted its position in TESARO by 20.0% during the second quarter. Trellus Management Company LLC now owns 13,819 shares of the biopharmaceutical company’s stock valued at $615,000 after acquiring an additional 2,300 shares during the last quarter. Janney Montgomery Scott LLC purchased a new stake in TESARO during the second quarter valued at approximately $257,000. Finally, Skylands Capital LLC purchased a new stake in TESARO during the second quarter valued at approximately $182,000.

TESARO traded down $1.12, reaching $35.12, during mid-day trading on Friday, MarketBeat reports. The company had a trading volume of 1,140,033 shares, compared to its average volume of 1,452,475. The company has a debt-to-equity ratio of 3.74, a current ratio of 4.02 and a quick ratio of 3.56. The company has a market capitalization of $1.95 billion, a P/E ratio of -3.83 and a beta of 1.21. TESARO has a 12 month low of $34.54 and a 12 month high of $136.45.

TESARO (NASDAQ:TSRO) last issued its earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($2.98) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.56) by ($0.42). The company had revenue of $49.74 million during the quarter, compared to the consensus estimate of $56.34 million. TESARO had a negative return on equity of 177.92% and a negative net margin of 193.42%. TESARO’s revenue was up 1520.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($2.55) earnings per share. research analysts expect that TESARO will post -10.02 EPS for the current fiscal year.

About TESARO

Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.

See Also: Diversification For Individual Investors

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply